Imagine a world where a simple injection every two months could revolutionize the lives of breastfeeding women living with HIV. This is the promise of long-acting antiretroviral therapy (ART), a potential game-changer for these women and their infants. But here's where it gets controversial: is this innovative treatment cost-effective, and will it be accessible to those who need it most?
Sujata Tewari and Dr. Andrea L. Ciaranello, experts from the Medical Practice Evaluation Center (MPEC) at Massachusetts General Hospital, set out to answer these questions. Their study, published in the Journal of Infectious Diseases, focused on Zimbabwe, a country with a high prevalence of maternal HIV, where this life-changing therapy is not yet widely available.
The researchers used sophisticated modeling techniques to evaluate the impact of long-acting injectable ART, specifically LA cabotegravir with rilpivirine (CAB/RPV), on the health of breastfeeding women and their infants. They compared this treatment to the standard daily oral ART, asking: what if we could offer this new therapy to postpartum women in Zimbabwe?
The results were eye-opening. For women whose HIV was not fully suppressed by oral pills at the time of delivery, switching to LA-CAB/RPV could prevent up to 160 infant infections annually in Zimbabwe. And for those women who had achieved viral suppression but struggled with daily pill adherence, LA-CAB/RPV offered a cost-effective solution if priced at $84/year or lower.
But here's the part most people miss: this study highlights the potential of long-acting ART formulations to improve the lives of people living with HIV, especially those who struggle with daily oral regimens. It's a call to action for global accessibility and affordability of these treatments.
As we look to the future, the researchers plan to continue their vital work, evaluating the impact of newer long-acting ART formulations among pregnant and breastfeeding women.
So, what do you think? Should long-acting ART be made available globally at an affordable price? The floor is open for discussion.
Related Stories:
- Killer T cell traits and long-term HIV remission
- Starting HIV drugs within days of infection: what's the impact?
- New rapid test distinguishes real HIV infections from vaccine-related false positives
